Key Points
-
Although great efforts have been made to address the bioavailability and tissue targeting of drugs, little is known about drug delivery to specific subcellular compartments that harbour the drug target. As cells constantly traffic their contents to these compartments, cell biology principles could be effectively used for drug targeting.
-
For a drug to reach particular subcellular compartments, the drug has to be modified to include the appropriate signal to target it to the subcellular site, without compromising its functional moiety.
-
Protein modifications or lipid conjugations that direct a drug to targets in the plasma membrane have been shown to increase drug efficacy. These modifications reduce the dimensionality of these otherwise soluble drugs, thereby leading to an increase in effective drug concentration.
-
Cells internalize various small molecules, nutrients and pathogens and sort them to specific intracellular compartments. Drug conjugation to either the nutrient moieties or part of the pathogens that carry the targeting signal are some of the strategies used to target specific organelles.
-
In addition to membrane-bound organelles, the cytosol could also be targeted by specific modifications. Cell-penetrating peptides from viruses, viral particles, bacterial toxins, liposomes and nanoparticles are various means to target the cytosol. Targeting the cytosol is also a method for reaching the nuclear compartment.
-
Specific targeting of drugs to subcellular compartments is still in the early stages of development but shows promise. Issues such as drug stability in intracellular compartments and tissue-specific targeting are still to be addressed.
Abstract
Many drug targets are localized to particular subcellular compartments, yet current drug design strategies are focused on bioavailability and tissue targeting and rarely address drug delivery to specific intracellular compartments. Insights into how the cell traffics its constituents to these different cellular locations could improve drug design. In this Review, we explore the fundamentals of membrane trafficking and subcellular organization, as well as strategies used by pathogens to appropriate these mechanisms and the implications for drug design and delivery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gershell, L. J. & Atkins, J. H. A brief history of novel drug discovery technologies. Nature Rev. Drug Discov. 2, 321–327 (2003). This article gives an excellent timeline on the development of various technologies in drug discovery.
Langer, R. Drug delivery. Drugs on target. Science 293, 58–59 (2001). A well written primer on the need for targeted drug delivery to reduce adverse effects.
Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001). An excellent reference for determining the bioavailability of drugs.
Rosen, H. & Abribat, T. The rise and rise of drug delivery. Nature Rev. Drug Discov. 4, 381–385 (2005).
Blobel, G. Protein targeting (Nobel lecture). Chembiochem 1, 86–102 (2000).
Gruenberg, J. & van der Goot, F. G. Mechanisms of pathogen entry through the endosomal compartments. Nature Rev. Mol. Cell Biol. 7, 495–504 (2006).
Simons, K. & Ikonen, E. Functional rafts in cell membranes. Nature 387, 569–572 (1997). The first detailed description of lipid rafts in cellular membranes and the implications for cellular signalling.
Zerial, M. & McBride, H. Rab proteins as membrane organizers. Nature Rev. Mol. Cell Biol. 2, 107–117 (2001). An important reference on the subcellular compartmentalization and the role of Rab GTPases in membrane trafficking.
Grassme, H. et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276, 20589–20596 (2001).
Heldin, C. H. Dimerization of cell surface receptors in signal transduction. Cell 80, 213–223 (1995).
Jordan, B. A. & Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697–700 (1999).
Schwyzer, R. Membrane-assisted molecular mechanism of neurokinin receptor subtype selection. EMBO J. 6, 2255–2259 (1987).
Schwyzer, R. How do peptides interact with lipid membranes and how does this affect their biological activity? Braz. J. Med. Biol. Res. 25, 1077–1089 (1992).
Kholodenko, B. N., Brown, G. C. & Hoek, J. B. Diffusion control of protein phosphorylation in signal transduction pathways. Biochem. J. 350, 901–907 (2000).
Kholodenko, B. N., Hoek, J. B. & Westerhoff, H. V. Why cytoplasmic signalling proteins should be recruited to cell membranes. Trends Cell Biol. 10, 173–178 (2000). A brilliant description of the reduction-in-dimensionality principle and its implications for cellular signalling. It details the importance of the membrane association of acylated proteins upon signalling and their recruitment to lipid rafts.
Este, J. A. & Telenti, A. HIV entry inhibitors. Lancet 370, 81–88 (2007).
Reeves, J. D. & Piefer, A. J. Emerging drug targets for antiretroviral therapy. Drugs 65, 1747–1766 (2005).
Hildinger, M. et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol. 75, 3038–3042 (2001). The first study to show that a membrane-anchored fusion inhibitor is superior to its soluble counterpart. The implications for the reduction-in-dimensionality principle are discussed.
Melikyan, G. B., Egelhofer, M. & von Laer, D. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J. Virol. 80, 3249–3258 (2006).
Ingallinella, P. et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl Acad. Sci. USA 106, 5801–5806 (2009).
Miyauchi, K., Kim, Y., Latinovic, O., Morozov, V. & Melikyan, G. B. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137, 433–444 (2009).
Boonyarattanakalin, S., Hu, J., Dykstra-Rummel, S. A., August, A. & Peterson, B. R. Endocytic delivery of vancomycin mediated by a synthetic cell surface receptor: rescue of bacterially infected mammalian cells and tissue targeting in vivo. J. Am. Chem. Soc. 129, 268–269 (2007).
Rajendran, L. et al. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 320, 520–523 (2008). This work showed that an inactive inhibitor of β-secretase was rendered active by membrane anchoring through lipid-conjugation and subsequent endosomal targeting.
Gripon, P., Cannie, I. & Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79, 1613–1622 (2005).
Petersen, J. et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotech. 26, 335–341 (2008).
George, S. R., O'Dowd, B. F. & Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 1, 808–820 (2002).
Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90–113 (2000).
Covic, L., Gresser, A. L., Talavera, J., Swift, S. & Kuliopulos, A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl Acad. Sci. USA 99, 643–648 (2002).
Covic, L., Misra, M., Badar, J., Singh, C. & Kuliopulos, A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nature Med. 8, 1161–1165 (2002).
Sheff, D. Endosomes as a route for drug delivery in the real world. Adv. Drug Deliv. Rev. 56, 927–930 (2004).
Pagano, R. E., Puri, V., Dominguez, M. & Marks, D. L. Membrane traffic in sphingolipid storage diseases. Traffic 1, 807–815 (2000).
Rajendran, L. et al. Alzheimer's disease β-amyloid peptides are released in association with exosomes. Proc. Natl Acad. Sci. USA 103, 11172–11177 (2006).
Sorkin, A. Cargo recognition during clathrin-mediated endocytosis: a team effort. Curr. Opin. Cell Biol. 16, 392–399 (2004).
Maxfield, F. R. & McGraw, T. E. Endocytic recycling. Nature Rev. Mol. Cell Biol. 5, 121–132 (2004).
Conner, S. D. & Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37–44 (2003).
Schmid, S. L. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu. Rev. Biochem. 66, 511–548 (1997).
Mukherjee, S., Ghosh, R. N. & Maxfield, F. R. Endocytosis. Physiol. Rev. 77, 759–803 (1997).
Sonnichsen, B., De Renzis, S., Nielsen, E., Rietdorf, J. & Zerial, M. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J. Cell Biol. 149, 901–914 (2000).
Han, W., Zhang, T., Yu, H., Foulke, J. G. & Tang, C. K. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol. Ther. 5, 1361–1368 (2006).
Miaczynska, M., Pelkmans, L. & Zerial, M. Not just a sink: endosomes in control of signal transduction. Curr. Opin. Cell Biol. 16, 400–406 (2004).
Sorkin, A. & Von Zastrow, M. Signal transduction and endocytosis: close encounters of many kinds. Nature Rev. Mol. Cell Biol. 3, 600–614 (2002).
Schenck, A. et al. The endosomal protein Appl1 mediates Akt substrate specificity and cell survival in vertebrate development. Cell 133, 486–497 (2008).
von Zastrow, M. & Sorkin, A. Signaling on the endocytic pathway. Curr. Opin. Cell Biol. 19, 436–445 (2007).
Miaczynska, M. et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 116, 445–456 (2004).
Kermorgant, S. & Parker, P. J. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J. Cell Biol. 182, 855–863 (2008).
Bokel, C., Schwabedissen, A., Entchev, E., Renaud, O. & Gonzalez-Gaitan, M. Sara endosomes and the maintenance of Dpp signaling levels across mitosis. Science 314, 1135–1139 (2006).
Coumailleau, F., Furthauer, M., Knoblich, J. A. & Gonzalez-Gaitan, M. Directional Delta and Notch trafficking in Sara endosomes during asymmetric cell division. Nature 458, 1051–1055 (2009).
Schulz, R., Wehmeyer, A. & Schulz, K. Opioid receptor types selectively cointernalize with G protein-coupled receptor kinases 2 and 3. J. Pharmacol. Exp. Ther. 300, 376–384 (2002).
Smith, A. E. & Helenius, A. How viruses enter animal cells. Science 304, 237–242 (2004).
Marsh, M. & Helenius, A. Virus entry: open sesame. Cell 124, 729–740 (2006).
Sandvig, K. & van Deurs, B. Membrane traffic exploited by protein toxins. Annu. Rev. Cell Dev. Biol. 18, 1–24 (2002).
Mercer, J. & Helenius, A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320, 531–535 (2008).
Lamaze, C. et al. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol. Cell 7, 661–671 (2001).
Grassart, A., Dujeancourt, A., Lazarow, P. B., Dautry-Varsat, A. & Sauvonnet, N. Clathrin-independent endocytosis used by the IL-2 receptor is regulated by Rac1, Pak1 and Pak2. EMBO Rep. 9, 356–362 (2008).
Mayor, S. & Pagano, R. E. Pathways of clathrin-independent endocytosis. Nature Rev. Mol. Cell Biol. 8, 603–612 (2007). An updated review that focuses mainly on the clathrin-independent endocytic routes and discusses newly identified pathways and cargoes.
Sabharanjak, S., Sharma, P., Parton, R. G. & Mayor, S. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev. Cell 2, 411–423 (2002).
Deinhardt, K., Berninghausen, O., Willison, H. J., Hopkins, C. R. & Schiavo, G. Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J. Cell Biol. 174, 459–471 (2006).
Schneider, A. et al. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28, 2874–2882 (2008).
Cabiaux, V. pH-sensitive toxins: interactions with membrane bilayers and application to drug delivery. Adv. Drug Deliv. Rev. 56, 987–997 (2004).
Caron, N. J., Quenneville, S. P. & Tremblay, J. P. Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem. Biophys. Res. Commun. 319, 12–20 (2004).
Asokan, A. & Cho, M. J. Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J. Pharm. Sci. 91, 903–913 (2002).
Vassar, R. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv. Drug Deliv. Rev. 54, 1589–1602 (2002).
Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113–123 (2003).
Ippoliti, R. et al. A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity. FASEB J. 9, 1220–1225 (1995).
Wellhoner, H. H., Neville, D. M. Jr, Srinivasachar, K. & Erdmann, G. Uptake and concentration of bioactive macromolecules by K562 cells via the transferrin cycle utilizing an acid-labile transferrin conjugate. J. Biol. Chem. 266, 4309–4314 (1991).
Leamon, C. P. & Reddy, J. A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 56, 1127–1141 (2004).
Kader, A., Davis, P. J., Kara, M. & Liu, H. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J. Control Release 55, 231–243 (1998).
Hilgenbrink, A. R. & Low, P. S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94, 2135–2146 (2005).
Lubgan, D., Jozwiak, Z., Grabenbauer, G. G. & Distel, L. V. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells. Cell. Mol. Biol. Lett. 14, 113–127 (2009).
Singh, M., Atwal, H. & Micetich, R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res. 18, 1423–1427 (1998).
Zhao, X., Li, H. & Lee, R. J. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 5, 309–319 (2008).
Gupta, Y., Jain, A., Jain, P. & Jain, S. K. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J. Drug Target 15, 231–240 (2007).
Dixit, V., Van den Bossche, J., Sherman, D. M., Thompson, D. H. & Andres, R. P. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug. Chem. 17, 603–609 (2006).
Beduneau, A. et al. Brain targeting using novel lipid nanovectors. J. Control Release 126, 44–49 (2008).
Gupta, Y., Jain, A. & Jain, S. K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 59, 935–940 (2007).
Ulbrich, K., Hekmatara, T., Herbert, E. & Kreuter, J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71, 251–256 (2009).
Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nature Rev. Mol. Cell Biol. 5, 554–565 (2004). A comprehensive review on the biochemistry, genetics and cell biology of lysosomal storage disease and various treatment strategies.
Grabowski, G. A. & Hopkin, R. J. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu. Rev. Genomics Hum. Genet. 4, 403–436 (2003).
Desnick, R. J., Thorpe, S. R. & Fiddler, M. B. Toward enzyme therapy for lysosomal storage diseases. Physiol. Rev. 56, 57–99 (1976).
Sly, W. S. et al. Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc. Natl Acad. Sci. USA 103, 15172–15177 (2006).
Zhu, Y., Li, X., Schuchman, E. H., Desnick, R. J. & Cheng, S. H. Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages. J. Pharmacol. Exp. Ther. 308, 705–711 (2004).
Mukherjee, S. & Maxfield, F. R. Lipid and cholesterol trafficking in NPC. Biochim. Biophys. Acta 1685, 28–37 (2004).
Liu, B. et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc. Natl Acad. Sci. USA 106, 2377–2382 (2009).
Johannes, L. & Decaudin, D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 12, 1360–1368 (2005).
Gariepy, J. The use of Shiga-like toxin 1 in cancer therapy. Crit. Rev. Oncol. Hematol. 39, 99–106 (2001).
Furukawa, K. et al. Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells: implication in the sensitivity to verotoxins. J. Biol. Chem. 277, 11247–11254 (2002).
Sillence, D. J. et al. Glucosylceramide modulates membrane traffic along the endocytic pathway. J. Lipid Res. 43, 1837–1845 (2002).
Gupta, B., Levchenko, T. S. & Torchilin, V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57, 637–651 (2005).
Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189–1193 (1988). One of the first reports on the cell-penetrating activity of Tat proteins.
Elliott, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223–233 (1997).
Wender, P. A. et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl Acad. Sci. USA 97, 13003–13008 (2000).
Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. & Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848–866 (2007).
Chen, B., Liu, Q., Zhang, Y., Xu, L. & Fang, X. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots. Langmuir 24, 11866–11871 (2008).
Holowka, E. P., Sun, V. Z., Kamei, D. T. & Deming, T. J. Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery. Nature Mater. 6, 52–57 (2007).
Khalil, I. A. et al. Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther. 11, 636–644 (2004).
Futaki, S. et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug. Chem. 12, 1005–1011 (2001).
Murthy, N., Robichaud, J. R., Tirrell, D. A., Stayton, P. S. & Hoffman, A. S. The design and synthesis of polymers for eukaryotic membrane disruption. J. Control Release 61, 137–143 (1999).
Mastrobattista, E. et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J. Biol. Chem. 277, 27135–27143 (2002).
Li, W., Nicol, F. & Szoka, F. C. Jr. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev. 56, 967–985 (2004).
Leopold, P. L. & Crystal, R. G. Intracellular trafficking of adenovirus: many means to many ends. Adv. Drug Deliv. Rev. 59, 810–821 (2007).
Abrami, L., Lindsay, M., Parton, R. G., Leppla, S. H. & van der Goot, F. G. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J. Cell Biol. 166, 645–651 (2004).
Le Blanc, I. et al. Endosome-to-cytosol transport of viral nucleocapsids. Nature Cell Biol. 7, 653–664 (2005).
Duncan, R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem. Soc. Trans. 35, 56–60 (2007).
Kreitman, R. J. Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 5, 44–51 (2003).
Sun, Q., Cai, S. & Peterson, B. R. Selective disruption of early/recycling endosomes: release of disulfide-linked cargo mediated by a N.-alkyl-3beta-cholesterylamine-capped peptide. J. Am. Chem. Soc. 130, 10064–10065 (2008).
Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nature Rev. Drug Discov. 8, 129–138 (2009).
Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982–12987 (2007).
Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotech. 26, 561–569 (2008). An excellent article describing the use of lipid-conjugated RNAi molecules for therapeutic purposes.
de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nature Rev. Drug Discov. 6, 443–453 (2007).
Berg, K. et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 59, 1180–1183 (1999).
Kamiya, H., Tsuchiya, H., Yamazaki, J. & Harashima, H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv. Drug Deliv. Rev. 52, 153–164 (2001).
Nabi, I. R. & Le, P. U. Caveolae/raft-dependent endocytosis. J. Cell Biol. 161, 673–677 (2003).
Li, S. & Huang, L. Nonviral gene therapy: promises and challenges. Gene Ther. 7, 31–34 (2000).
Goula, D. et al. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 5, 1291–1295 (1998).
Budker, V., Gurevich, V., Hagstrom, J. E., Bortzov, F. & Wolff, J. A. pH-sensitive, cationic liposomes: a new synthetic virus-like vector. Nature Biotech. 14, 760–764 (1996).
Farokhzad, O. C. & Langer, R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58, 1456–1459 (2006).
Yu, D. et al. The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J. 272, 3651–3660 (2005).
Yamada, T. et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature Biotech. 21, 885–890 (2003).
Farokhzad, O. C. & Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 3, 16–20 (2009).
Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2, 751–760 (2007).
Nagaoka, T. et al. Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. J. Control Release 118, 348–356 (2007).
Schroder, T. et al. Peptoidic amino- and guanidinium-carrier systems: targeted drug delivery into the cell cytosol or the nucleus. J. Med. Chem. 51, 376–379 (2008).
Sen, N. & Majumder, H. K. Mitochondrion of protozoan parasite emerges as potent therapeutic target: exciting drugs are on the horizon. Curr. Pharm. Des. 14, 839–846 (2008).
Muratovska, A., Lightowlers, R. N., Taylor, R. W., Wilce, J. A. & Murphy, M. P. Targeting large molecules to mitochondria. Adv. Drug Deliv. Rev. 49, 189–198 (2001).
Pilkington, G. J., Parker, K. & Murray, S. A. Approaches to mitochondrially mediated cancer therapy. Semin. Cancer Biol. 18, 226–235 (2008).
Debatin, K. M., Poncet, D. & Kroemer, G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21, 8786–8803 (2002).
Murphy, M. P. Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta 1777, 1028–1031 (2008).
Szeto, H. H. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann. NY Acad. Sci. 1147, 112–121 (2008).
Kang, B. H. et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 119, 454–464 (2009).
Kang, B. H. et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131, 257–270 (2007). References 129 and 130 describe the mitochondrion-specific HSP90 protein network and the design of a drug aimed at inhibiting this organelle-specific network.
Di Paolo, G. & De Camilli, P. Phosphoinositides in cell regulation and membrane dynamics. Nature 443, 651–657 (2006). An excellent review on the role of PIPs in cellular signalling and intracellular trafficking.
Wymann, M. P. & Schneiter, R. Lipid signalling in disease. Nature Rev. Mol. Cell Biol. 9, 162–176 (2008).
Hammond, G. R. & Schiavo, G. Polyphosphoinositol lipids: under-PPInning synaptic function in health and disease. Dev. Neurobiol. 67, 1232–1247 (2007).
Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244–1247 (2008).
Lecuyer, E. et al. Global analysis of mRNA localization reveals a prominent role in organizing cellular architecture and function. Cell 131, 174–187 (2007).
Besse, F. & Ephrussi, A. Translational control of localized mRNAs: restricting protein synthesis in space and time. Nature Rev. Mol. Cell Biol. 9, 971–980 (2008).
Siegel, G. et al. A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nature Cell Biol. 11, 705–716 (2009).
Gibbings, D. J., Ciaudo, C., Erhardt, M. & Voinnet, O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nature Cell Biol. 11, 1143–1149 (2009).
Lee, Y. S. et al. Silencing by small RNAs is linked to endosomal trafficking. Nature Cell Biol. 11, 1150–1156 (2009). References 137–139 demonstrate that regulatory RNAs are compartmentalized in the cell and require membrane trafficking components for their function.
Miyashiro, K. Y., Bell, T. J., Sul, J. Y. & Eberwine, J. Subcellular neuropharmacology: the importance of intracellular targeting. Trends Pharmacol. Sci. 30, 203–211 (2009).
Panakova, D., Sprong, H., Marois, E., Thiele, C. & Eaton, S. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 435, 58–65 (2005).
Fevrier, B., Vilette, D., Laude, H. & Raposo, G. Exosomes: a bubble ride for prions? Traffic 6, 10–17 (2005).
Spencer, B. J. & Verma, I. M. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl Acad. Sci. USA 104, 7594–7599 (2007). This study reports lentivirus-mediated gene delivery into the brain using the LDL receptor-binding domain of APOB.
Eggeling, C. et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 457, 1159–1162 (2009).
Fantini, J., Garmy, N., Mahfoud, R. & Yahi, N. Lipid rafts: structure, function and role in, HIV, Alzheimer's and prion diseases. Expert Rev. Mol. Med. 4, 1–22 (2002).
Nayak, D. P., Hui, E. K. & Barman, S. Assembly and budding of influenza virus. Virus Res. 106, 147–165 (2004).
Popik, W., Alce, T. M. & Au, W. C. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells. J. Virol. 76, 4709–4722 (2002).
Manes, S. et al. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 1, 190–196 (2000).
Nguyen, D. H. & Taub, D. D. Targeting lipids to prevent HIV infection. Mol. Interv. 4, 318–320 (2004).
Khanna, K. V. et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 109, 205–211 (2002).
Cranage, M. et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5, e157; discussion e157 (2008).
Verma, S. P. HIV: a raft-targeting approach for prevention and therapy using plant-derived compounds (review). Curr. Drug Targets. 10, 51–59 (2009).
Scheiffele, P., Rietveld, A., Wilk, T. & Simons, K. Influenza viruses select ordered lipid domains during budding from the plasma membrane. J. Biol. Chem. 274, 2038–2044 (1999).
Ali, A., Avalos, R. T., Ponimaskin, E. & Nayak, D. P. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J. Virol. 74, 8709–8719 (2000).
Murphy, S. C. et al. Lipid rafts and malaria parasite infection of erythrocytes. Mol. Membr. Biol. 23, 81–88 (2006).
Samuel, B. U. et al. The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J. Biol. Chem. 276, 29319–29329 (2001).
Ferguson, M. A. Glycosylphosphatidylinositol biosynthesis validated as a drug target for African sleeping sickness. Proc. Natl Acad. Sci. USA 97, 10673–10675 (2000).
Cheng, H. et al. Mechanisms of Disease: new therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts. Nature Clin. Pract. Neurol. 3, 374–382 (2007).
Hooper, N. M. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem. Soc. Trans. 33, 335–338 (2005).
Holowka, D. et al. Lipid segregation and IgE receptor signaling: a decade of progress. Biochim. Biophys. Acta 1746, 252–259 (2005).
Gidwani, A., Brown, H. A., Holowka, D. & Baird, B. Disruption of lipid order by short-chain ceramides correlates with inhibition of phospholipase D and downstream signaling by FceRI. J. Cell Sci. 116, 3177–3187 (2003).
Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotech. 23, 1002–1007 (2005).
Aouadi, M. et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458, 1180–1184 (2009).
Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotech. 25, 1149–1157 (2007).
Mukherjee, S., Soe, T. T. & Maxfield, F. R. Endocytic sorting of lipid analogues differing solely in the chemistry of their hydrophobic tails. J. Cell Biol. 144, 1271–1284 (1999).
van Meer, G. Cellular lipidomics. EMBO J. 24, 3159–3165 (2005).
Fivaz, M. et al. Differential sorting and fate of endocytosed GPI-anchored proteins. EMBO J. 21, 3989–4000 (2002).
van Meer, G. & Sprong, H. Membrane lipids and vesicular traffic. Curr. Opin. Cell Biol. 16, 373–378 (2004).
Pellizzari, A., Pang, H. & Lingwood, C. A. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 31, 1363–1370 (1992).
Kiarash, A., Boyd, B. & Lingwood, C. A. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 269, 11138–11146 (1994).
Koivusalo, M., Jansen, M., Somerharju, P. & Ikonen, E. Endocytic trafficking of sphingomyelin depends on its acyl chain length. Mol. Biol. Cell 18, 5113–5123 (2007). This work illustrates the utility of different sphingomyelin species for targeting drugs to different subcellular compartments.
Boonyarattanakalin, S., Martin, S. E., Dykstra, S. A. & Peterson, B. R. Synthetic mimics of small Mammalian cell surface receptors. J. Am. Chem. Soc. 126, 16379–16386 (2004).
Acknowledgements
We thank M. Zerial, I. Levental, J. Ries, V. Kotelianski, C. Schroeder, Z. Maliga, G. Kalyanaraman and G. Jennings for their insightful comments on the work. We acknowledge the funding support from the Swiss National Foundation (NCCR Neuro) and a grant from Alzheimer Forschungs Initiative e.V to L.R.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
H.-J.K. and K.S. are co-founders of the biotechnology company JADO Technologies, which specializes in membrane invention technologies including lipid raft modulation.
Related links
Related links
DATABASES
OMIM
FURTHER INFORMATION
Glossary
- Endosome
-
A membrane-bound vesicle that is formed by the invagination of the plasma membrane during endocytosis.
- Clathrin triskelion
-
A clathrin structure that consists of three heavy chains and three light chains that weave together to form three 'legs' radiating from a central point. The heavy chains form the backbone whereas the light chains are involved in the formation of clathrin lattices.
- Prodrug
-
A drug that is designed to release the active moiety only upon certain activating conditions.
- Transition state inhibitor
-
Inhibitors that are designed to mimic the transition state of a substrate molecule in the enzyme–substrate catalytic reaction. Such inhibitors do not undergo catalysis and inhibit the enzyme at the substrate-binding site.
- Bioavailability
-
The extent to and rate at which the drug enters the systemic circulation.
- Small interfering RNA
-
(siRNA). Small stretches of RNA, usually 21–25 nucleotides long, that bind to mRNA and target it for degradation, thereby silencing gene expression.
- Singlet oxygen
-
A form of molecular oxygen that is a reactive oxygen species and less stable than the normal triplet oxygen.
- Blood–brain barrier
-
A semi-permeable cellular structure consisting of endothelial cells that allows selective passage of some molecules but prevents the passage of others.
Rights and permissions
About this article
Cite this article
Rajendran, L., Knölker, HJ. & Simons, K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 9, 29–42 (2010). https://doi.org/10.1038/nrd2897
Issue Date:
DOI: https://doi.org/10.1038/nrd2897
This article is cited by
-
Protein transfection via spherical nucleic acids
Nature Protocols (2022)
-
γ-Secretase in Alzheimer’s disease
Experimental & Molecular Medicine (2022)
-
Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches
Journal of Pharmaceutical Investigation (2022)
-
Nanotechnology for Enhanced Cytoplasmic and Organelle Delivery of Bioactive Molecules to Immune Cells
Pharmaceutical Research (2022)
-
In silico analysis and molecular identification of an anaphase-promoting complex homologue from human pathogen Entamoeba histolytica
Journal of Genetic Engineering and Biotechnology (2021)